Related content

Pharmacogenomics and “Individualized Drug Therapy”: High Expectations and Disappointing Achievements

By Nebert D.W.  

American Journal of PharmacoGenomics, Vol. 3, Iss. 6, 2003-01 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite

Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy

By Mango Ruggiero   Vecchione Lucia   Raso Barbara   Borgiani Paola   Brunetti Ercole   Mehta Jawahar L   Lauro Renato   Romeo Francesco   Novelli Giuseppe  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. : 2565-2576

Informa Healthcare

Access to resources Recommend Favorite

The genetics of aging – implications for pharmacogenomics

By Perls Thomas   Puca Annibale  

Pharmacogenomics, Vol. 3, Iss. 4, 2002-07 ,pp. : 469-484

Future Medicine

Access to resources Recommend Favorite

Mouse genetics in drug target discovery and validation: no simple answers to complex problems

By Russ AP   Grosse J  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 10, 2007-10 ,pp. : 1379-1387

Informa Healthcare

Access to resources Recommend Favorite

Drug Target Pharmacogenomics: An Overview

By Johnson J.A.  

American Journal of PharmacoGenomics, Vol. 1, Iss. 4, 2001-01 ,pp. : 271-281

Adis International

Access to resources Recommend Favorite